BIRAC and the French Embassy in India, represented by the Science and Technology Service (SST) have joined hands to support Indian and French collaborative projects in Red Biotechnology up to pre-commercialization stage in 2 + 2 model involving academic actors, biotech start-ups and SMEs for promoting the innovation ecosystem in both the countries. On behalf of BIRAC & French Embassy in India, CEFIPRA is managing this programme.
Under this programme, the support will be provided for challenge-oriented, high-quality solution-driven bilateral projects that i) combine innovative approaches towards new concepts and technological breakthroughs in human health, ii) encourage and enable Indo-French collaboration between public and private research groups, industry, clinicians and end-users in order to improve the competitiveness of both Indian and French biotech industries.
The proposals must be innovative and market-driven towards the development or substantial improvement of new products, devices, drugs, processes, etc. for human health.
Support High-quality bilateral research projects that combine innovative approaches towards new concepts and technological breakthroughs
Encourage and enable Indo-French collaboration between public and private research groups, industry, clinicians and end-users.
The funded projects are expected to lead to innovative technology developments for human health and knowledge transfer towards either clinical or industrial applications.
Molecular diagnostics for prediction of diseases like Cardiac, Alzheimer’s, Cerebral Palsy (New Assistive Technologies for mobility of Physically Challenged)
Who can apply
The proposals must involve at least two French partners (one academia and one industry) and two Indian partners (one academia and one industry), and should clearly show the added value of the bilateral collaboration.
Duration of the projects will not exceed 2 years. Maximum two projects will be supported under this programme. The proposals must be written jointly by Indian and French partners.